These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22350572)

  • 1. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients.
    Dalkilic E; Bulbul Baskan E; Alkis N; Gullulu M; Yavuz M; Dilek K; Ersoy A; Yurtkuran M
    Mod Rheumatol; 2012 Sep; 22(5):738-42. PubMed ID: 22350572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.
    Kary S; Worm M; Audring H; Huscher D; Renelt M; Sörensen H; Ständer E; Maass U; Lee H; Sterry W; Burmester GR
    Ann Rheum Dis; 2006 Mar; 65(3):405-7. PubMed ID: 16150791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
    Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
    Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?
    Cuchacovich R; Espinoza CG; Virk Z; Espinoza LR
    J Clin Rheumatol; 2008 Dec; 14(6):353-6. PubMed ID: 19033869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.
    Wendling D; Balblanc JC; Briançon D; Brousse A; Lohse A; Deprez P; Humbert P; Aubin F
    Joint Bone Spine; 2008 May; 75(3):315-8. PubMed ID: 18329935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
    Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L
    Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412
    [No Abstract]   [Full Text] [Related]  

  • 10. New-onset psoriasis associated with etanercept therapy.
    Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
    J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract]   [Full Text] [Related]  

  • 12. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.
    Grinblat B; Scheinberg M
    Semin Arthritis Rheum; 2008 Feb; 37(4):251-5. PubMed ID: 17640718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study.
    Davaine AC; Saraux A; Prigent S; Kupfer-Bessaguet I; Roswag D; Plantin P; Schoenlaub P; Talarmin F; Zagnoli A; Misery L
    J Eur Acad Dermatol Venereol; 2008 Dec; 22(12):1471-7. PubMed ID: 18713230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pustular skin lesions in patients treated with infliximab: report of two cases.
    Starmans-Kool MJ; Peeters HR; Houben HH
    Rheumatol Int; 2005 Sep; 25(7):550-2. PubMed ID: 15711788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
    Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
    J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.
    Laga AC; Vleugels RA; Qureshi AA; Velazquez EF
    Am J Dermatopathol; 2010 Aug; 32(6):568-73. PubMed ID: 20520526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis and granuloma formation in patients receiving anti-TNF therapy.
    Iliopoulos A; Psathakis K; Aslanidis S; Skagias L; Sfikakis PP
    Int J Tuberc Lung Dis; 2006 May; 10(5):588-90. PubMed ID: 16704045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor-alpha-induced psoriasis.
    Sari I; Akar S; Birlik M; Sis B; Onen F; Akkoc N
    J Rheumatol; 2006 Jul; 33(7):1411-4. PubMed ID: 16821276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.